Welcome to the BioLogicTube

suPAR - From basic research to routine clinical use - Danish speak

Sun, 10 Apr 2016 20:54:55 GMT

suPAR is today a routine marker used for accessing disease severity and prognosis in the Emergency Department. The movie is produced by Copenhagen University Hodpital Hvidovre. Photo and edit Peter Bak

Overview of the 5'th International suPAR symposium

Fri, 25 Jul 2014 14:38:49 GMT

The 5th suPAR symposium was hosted by Prof. Markus Schultz and held at the Amsterdam Medical Center in May 2014. New and recently published data were presented and gave insights into the clinical use of suPAR. This years focus was on the use of suPAR as a risk triage marker in the Acute Medical Department. Data from the routine use as well research data complemented into a conclusion that suPAR helps changing the clinical decision. Should the patient be admitted? Sent home? Rushed to the ICU? This and more was discussed by almost 100 clinicians and researchers over the 2-day seminar.

Dr. August Wrotek talks on suPAR as marker of severity of pneumonia in children

Fri, 13 Jun 2014 11:43:12 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Wrotek's presentation was one of 25 lectures given over the 2-day 5'th International suPAR symposium. The programme and info on the conference can be found here: www.ViroGates.com

Dr. Martin Höenigl talks on suPAR and risk stratification in the Acute care...

Fri, 13 Jun 2014 10:47:56 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Höenigll's presentation was one of 25 lectures given over the 2-day Internationl suPAR symposium and The groups work was published in Journal of Internal Medicine in 2014 (http://www.ncbi.nlm.nih.gov/pubmed/24645798) and was accompaigned by an editorial (http://www.ncbi.nlm.nih.gov/pubmed/24734882).

Lifandis - Unlocking the secrets of disease

Wed, 09 Apr 2014 14:29:18 GMT

Lifandis links the industry to a wealth of biological samples from the HUNT studies. It is the entry point to a unique set of biological samples and extensive clinical and longitudinal data based on the Norwegian population. By connecting industry to high quality biosamples, a comprehensive network of national health registries, and depth information about health and disease we offer unparalleled access to this population.

Lifandis advances disease understanding and leads to better healthcare products.

Lifandis is owned by the Norwegian University of Science and Technology, the Central Norway Health Authority and the Nord-Trøndelag County.

The company changed its name from Hunt Biosciences AS to Lifandis AS as of April 1, 2014.

For more info, please check www.lifandis.com

suPAR as a prognostic biomarker in the acute care setting

Tue, 05 Jun 2012 21:01:45 GMT

A simple suPAR measurement has similar or better predictive value of mortality than SOFA score (sequential organ failure assessment score), a sepsis mortality risk algorithm including multiple laboratory and clinical measures. This and other aspects of the use of suPAR in an acute care setting was discussed at the 2nd International suPAR symposium in Copenhagen, Denmark 2011

The crystal ball biomarker - is your life killing you?

Tue, 05 Jun 2012 20:55:49 GMT

The suPAR molecule and its predictive value and role as a life style and risk biomarker is discussed at the second international suPAR symposium in Copenhagen 2011